Zusammenfassung
Die adjuvante Therapie von Patienten mit einem Kolonkarzinom erfolgt gemäß bestimmten Risikogruppen. Im UICC-Stadium III ist die adjuvante Therapie mit einer oxaliplatinhaltigen Chemotherapie (Folfox oder Capox) indiziert (Empfehlungsgrad A). Bei Patienten, die keine Kombinationschemotherapie erhalten können, sollte Capecitabin als Monosubstanz eingesetzt werden. Bei Patienten im Stadium II entscheiden weiterhin die bekannten klinischen und pathologischen Risikofaktoren wie T4-Kategorie, zu wenige untersuchte Lymphknoten, Notfalloperation oder Tumoreinriss/-perforation über die Indikation für eine adjuvante Chemotherapie. Liegen solche Risikofaktoren vor, so sollte eine adjuvante Therapie mit einem Fluoropyrimidin eingeleitet werden. Keiner dieser Risikofaktoren ist bislang prospektiv validiert. Oxaliplatin hat im Stadium II keinen Stellenwert, da der absolute Überlebensbenefit gering ist. Für Patienten ohne klinische Risikofaktoren besteht eine „Kann“-Empfehlung für eine adjuvante Therapie auf dem Boden der QUASAR-Studie. Die US-amerikanischen Empfehlungen sehen hingegen keine Indikation für eine adjuvante Therapie im Stadium II ohne Risikofaktoren.
Abstract
Adjuvant treatment of colon cancer is recommended according to the initial UICC stage of the disease and certain risk factors. If lymph nodes are afflicted (UICC stage III) combination chemotherapy with oxaliplatin and fluoropyrimidines (5-FU or capecitabine) should be administered (evidence level 1a, recommendation level A) following data from the French MOSAIC study. If patients do not qualify for combination treatment monotherapy with fluoropyrimidines should be given preferably with capecitabine. In UICC stage II cancer the recommendation for adjuvant therapy depends on the presence of certain risk factors such as T4 category, emergency surgery, perforation and insufficient lymph nodes examined (less than 12), and patients should then receive adjuvant chemotherapy with fluoropyrimidines. However, none of these risk factors have been validated prospectively and the predictive value is unclear. Oxaliplatin should not be added in stage II cancer. If patients are diagnosed with stage II cancer without risk factors then fluoropyrimidines may be given according to the results of the QUASAR study. In contrast, the ASCO guidelines do not recommend chemotherapy for stage II patients without risk factors.
Literatur
Alberts SR, Sargent DJ, Smyrk TC et al (2010) Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): results from NCCTG Intergroup Phase III Trial N0147. J Clin Oncol 28 (Suppl 18): A-CRA3507 (Abstract)
Allegra CJ, Yothers G, O’Connell MJ et al (2011) Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 29: 11–16
André T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27: 3109–3116
Benson AB III, Ajani JA, Catalano RB et al (2004) Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22: 2918–2926
Biagi JJ, Raphael MJ, Mackillop WJ et al (2011) Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA 305: 2335–2342
De Gramont A, Van Cutsem E, Tabernero J et al (2011) Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer. J Clin Oncol 29 (Suppl 4): Abstr 362
Gill S, Loprinzi CL, Sargent DJ et al (2004) Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22: 1797–1806
Haller DG, Tabernero J, Maroun J et al (2011) Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 29: 1465–1471
Hutchins G, Southward K, Handley K et al (2011) Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 29: 1261–1270
Jover R, Nguyen TP, Pérez-Carbonell L et al (2011) 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology 140: 1174–1181
Kerr D, Gray R, Quirke P et al (2009) A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. J Clin Oncol 27 (Suppl): 15s (Abstr 4000)
Martínez-López E, Abad A, Font A et al (1998) Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer. Gastroenterology 114: 1180–1187
Merkel S, Wein A, Günther K et al (2001) High-risk groups of patients with Stage II colon carcinoma. Cancer 92: 1435–1443
Morris M, Platell C, Boer B de et al (2006) Population-based study of prognostic factors in stage II colonic cancer. Br J Surg 93: 866–871
O’Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new american joint committee on cancer sixth edition staging. J Natl Cancer Inst 96: 1420–1425
O’Connell MJ, Lavery I, Yothers G et al (2010) Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol 28: 3937–3944
O’Connor ES, Greenblatt DY, LoConte NK et al (2011) Adjuvant chemotherapy for stage ii colon cancer with poor prognostic features. J Clin Oncol 29: 3381–3388
Ogino S, Nosho K, Kirkner GJ et al (2009) CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. GUT 58: 90–96
Petersen VC, Baxter KJ, Love SB, Shepherd NA (2002) Identification of objective pathological prognostic determinants and models of prognosis in Dukes‘ B colon cancer. GUT 51: 65–69
QUASAR Collaborative Group (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370 (9604): 2020–2029
Ribic CM, Sargent DJ, Moore MJ et al (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349: 247–257
Rosenberg R, Maak M, Simon I et al (2011) Independent validation of a prognostic genomic profile (ColoPrint) for stage II colon cancer (CC) patients. J Clin Oncol 29 (Suppl 4): Abstr 358
Salazar R, Roepman P, Capella G et al (2011) Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 29: 17–24
Sargent DJ, Marsoni S, Thibodeau N et al (2008) Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): a pooled molecular reanalysis of randomized chemotherapy trials. J Clin Oncol 26 (Suppl): Abstr 4008
Schmiegel W, Pox C, Arnold D et al (2009) Colorectal carcinoma: the management of polyps, (neo)adjuvant therapy, and the treatment of metastases. Dtsch Ärztebl Int 106(51–52): 843–848
Schmiegel W, Reinacher-Schick A, Arnold D et al (2008) Update S3-guideline „colorectal cancer“ 2008. Z Gastroenterol 46: 799–840
Sinicrope FA, Foster NR, Thibodeau SN et al (2011) DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 103: 863–875
Teixeira L, Hickish T, Tournigand C et al (2010) Efficacy of FOLFOX4 as adjuvant therapy in stage II colon cancer (CC): A new analysis of the MOSAIC trial according to risk factors. J Clin Oncol 28: 15S(Suppl 3524)
Tejpar S (2010) Adjuvant chemotherapy for stage ii colon cancer: Are we closer to finding the patients who benefit? In: ASCO 2010 Educational Book
Tejpar S, Bosman F, Delorenzi M et al (2009) Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial). J Clin Oncol 27: 15S (Abstr 4001)
Twelves C, Wong A, Nowacki MP et al (2005) Capecitabine as Adjuvant Treatment for Stage III Colon Cancer. N Engl J Med 352: 2696–2704
Van Cutsem E, Labianca R, Bodoky G et al (2009) Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage iii colon cancer: petacc-3. J Clin Oncol 27: 3117–3125
Walther A, Johnstone E, Swanton C et al (2009) Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 9: 489–499
Wittekind C, Meyer HJ (Hrsg) (2010) UICC: TNM Klassifikation maligner Tumoren, 7. Aufl. Wiley-VCH, Weinheim, ISBN 978-3-527-32759-1
Wittekind C, Meyer HJ, Bootz F (Hrsg) (2002) UICC: TNM Klassifikation maligner Tumoren, 6. Aufl. Springer, Berlin Heidelberg New York, ISBN 3-540-43664-2
Yothers GA, Allegra CJ, O’Connell MJ et al (2011) The efficacy of oxaliplatin (Ox) when added to 5-fluorouracil/leucovorin (FU/L) in stage II colon cancer. J Clin Oncol 29 (Suppl): Abstr 3507
Interessenskonflikt
Die Autorin weist auf folgende Beziehungen hin: Honoraria von Amgen, Roche, Pfizer, Sanofi-Aventis; Advisory-Board-Teilnahme bei Amgen, Roche, Pfizer und Merck; Unterstützung für Studien und Forschungsprojekte von Roche und Sanofi-Aventis.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Reinacher-Schick, A. Risikoadaptierte adjuvante Therapie des Kolonkarzinoms. Gastroenterologe 7, 14–23 (2012). https://doi.org/10.1007/s11377-011-0606-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11377-011-0606-1